@FierceBiotech: ICYMI, check out newest Industry Voices: Time to Take Fecal Transplantation Seriously. Feature | Follow @FierceBiotech
@JohnCFierce: Seems likely to me that Merck is going to cut open R&D and do some major surgery. Perlmutter is two weeks on the job. | Follow @JohnCFierce
@RyanMFierce: Just talked to Semantelli about IMS Health deal: IMS Health acquires social media analytics startup Semantelli. Report | Follow @RyanMFierce
> Oxford BioMedica struck a deal with Novartis ($NVS) to manufacture clinical grade material with its LentiVector gene delivery technology. Release
> Novo Nordisk ($NVO) today handed investors a 28% bump in first-quarter profits as it rode better-than-expected sales of both its insulin products and its diabetes treatment Victoza. Its net income was 5.98 billion kroner ($1.1 billion), Bloomberg reported. Yet in mid-morning trading in the U.S., shares were off 1.25%. Report
Pharma News
@FiercePharma: Scary-odd news from Bloomberg: Amgen blood drugs may help victims survive nuclear attack. Story | Follow @FiercePharma
@EricPFierce: FDA tests the waters on Plan B, approves it for girls 15 and older, off the shelf but requires proof of age. Report | Follow @EricPFierce
> Novo's exceptional first quarter still disappoints. Report
> Amgen blood drugs may help humans survive nuclear attack, FDA says. Article
> Lagging Januvia weighs on Merck's none-too-pretty first quarter. More
@FierceMedDev: Natera hauls in $54.6M for prenatal Dx. News | Follow @FierceMedDev
@MarkHFierce: An MRI scan to measure rain atrophy could predict MS, a new University at Buffalo study has determined. More | Follow @MarkHFierce
@DamianFierce: Join us for a trip through why a repeal of the medical device tax is unlikely to happen any time soon. Editor's corner | Follow @DamianFierce
> Hospira pulling the plug on troubled devices. Report
> Fresenius Medical watches profits slip amid U.S. struggles. Article
> Cardiovascular Systems addresses U.S. govt. info request in insider trader investigation. Item
Biomarkers News
> Dozens of new biomarkers gauge ovarian cancer survival prospects. Report
> Investigators profile a lethal tumor cell that could spur metastasis. Article
> Verastem gears up for companion Dx mesothelioma treatment trial. More
> Brain atrophy could predict MS, study finds. Story
> Key biomarker measure + CT scan predict melanoma survival odds. Item
Drug Delivery News
@MichaelGFierce: Merck, Celgene cancer nanomeds combined for better delivery. Report | Follow @MichaelGFierce
> Researchers open window through blood-brain barrier. Story
> ClearPoint MRI-guided device sheds light on drug delivery to the brain. Editor's corner
> 'Spider' protein can deliver stable vaccines in high concentration. More
> Insuline's InsuPatch delivery device suffers FDA setback. Item
And Finally… Researchers from Massachusetts General Hospital and Harvard University have discovered a possible new mechanism to halt the disease process in Alzheimer's. Blocking the activity of a little-known protein could clear beta-amyloid plaques that form in the brains of Alzheimer's patients--a hallmark of the disease. Story